Social News
Written by: Cao Jiajun
2021-01-13 07:09
Last update date: 2021-01-13 07:43
According to the clinical test data published by the Brazilian Butantan Institute, the "overall effective rate" of the new coronavirus pneumonia vaccine developed by China Kexing Biotechnology is only 50.4%.
The local health supervision bureau said that it would hold a meeting on the 17th to discuss whether to grant an emergency use license to Kexing Vaccine.
The preliminary data of the Phase III clinical trial conducted by Kexing in Brazil was originally scheduled to be available in early December last year, and then postponed to December 22 last year, and then postponed for 15 days until January 7 this year.
The Wall Street Journal reported at the time that the request to postpone the publication of the results was initiated by Kexing to the local Butantin Institute. The reason was that it hoped to wait for the results of tests in other places and then publish them after comprehensive analysis.
The Brazilian authorities stated on the 7th that the "clinical efficacy" of the Coxing vaccine is 78%, but the latest data is only 50.4%.
According to data, Kexing recruited 13,060 participants in Brazil for the third phase of clinical trials, which started on July 21 last year.
Brazilian President Jair Bolsonaro once criticized Coxing's vaccine effectiveness as "seems to be very low," but health officials rebelled against it, saying that the vaccine effectiveness is between 50% and 90%.
▼Kexing vaccine needs seven major steps from the laboratory to the market▼
+9
+9
+9
Voluntary test person was declared suicide after death
During the test of Coxing Vaccine in Brazil, there were deaths of voluntary testers. The Brazilian authorities once called the test to be stopped due to serious adverse reactions.
Later, after evaluating the data, he announced the resumption of relevant tests, and believed that the deceased had committed suicide.
Kexing is also conducting the third phase of clinical trials in Indonesia. The picture shows the vaccine prepared for air shipment from Beijing to Indonesia on December 6 last year.
(Associated Press)
In addition to Brazil, Kexing is also conducting Phase III clinical trials in Indonesia, involving 1,620 people.
Kexing revealed on December 8 last year that 97% of the participants in the trial in this place will develop antibodies after being vaccinated, that is, the positive conversion rate of serum antibodies is 97%, but having antibodies does not mean that the vaccine is effective to prevent infection with new coronary pneumonia.
The third phase of the Turkish clinical trial started on September 14 last year. It is expected that 13,000 participants will be recruited, but there are currently more than 7,000 participants.
Turkish Health Minister Fahrettin Koca was the first to announce the data of 1322 participants on Thursday (24th) local time. A total of 29 people were diagnosed. Among them, 3 were vaccinated with Koshin vaccine and the other 26 received comfort injections. The effective rate of the vaccine is 91.25%.
▼Protection rate side effects of Kexing, BioNTECH Fosun, AstraZeneca ▼
+2
+2
+2
Department of Health: is requesting vaccine clinical test data for evaluation
One of the three vaccines purchased by the Hong Kong government is Kexing vaccine.
The Hong Kong government stated earlier (8th) that before the start of injections in Hong Kong, pharmaceutical companies must provide the third phase clinical study data, production process and other information for application, and the Department of Health has contacted Kexing, hoping to obtain the vaccine CoronaVac in Brazil Perform clinical test data for evaluation.
Brazil's data indicates that the effective rate is only 50.4%. See the technology, price and side effects of Qingkexing vaccine
New crown pneumonia | Brazil said that the effective rate of Kexing vaccine is only over 50%, and it is decided on Sunday whether to use
Kexing vaccine effective rate is 78%. Department of Health: is requesting vaccine clinical test data for evaluation
01News
New crown pneumonia new crown vaccine